TP53 Gene Polymorphisms and Occupational Skin Cancer Risks for Workers of Glass Fiber Manufacture
AbstractBackground: Determining the role of genetic markers in individual sensitivity to chemical exposures raises a possibility of risk assessment of occupational diseases and their prevention. This paper focuses on the results of the identification of molecular-genetic markers associated with occupational skin cancer susceptibility. This study aimed to explore an association between polymorphisms of the TP53 tumor suppressor gene and a risk of developing occupational skin neoplasms.Methods: This case-control study was conducted on 71 workers with occupational skin neoplasms, 99 healthy workers, and 100 healthy population-based controls in Bashkortostan Republic, Russia in 2015. Genotyping of TP53 polymorphisms (rs1042522, rs1625895, and rs17878362) was performed by restriction fragment length polymorphism analysis of genomic DNA extracted from peripheral blood. Odds ratios and 95% confidence intervals were calculated to measure the strength of the association.Results: Subjects carrying allele C of rs1042522 were associated with an increased risk of occupational skin neoplasms [P=0.027, odds ratio (OR)=1.97, 95% confidence intervals (CI) 1.08-3.63]. An increased risk was also associated with allele 16bp of rs17878362 (P=0.010, OR=3.32, 95 % CI=1.31-8.78) and allele A of rs1625895 (P=0.003, OR = 5.45, 95 % CI = 1.72-19.15).Conclusion: The polymorphic variants rs1042522, rs1625895 and rs17878362 of the ТР53 gene are related to increased risks of occupational skin cancer. This study suggests the potential use of molecular-genetic data to assess increased individual risks of the development and prognosis of occupational skin neoplasms.
Koyuncuer A (2014). Histopathological evaluation of non-melanoma skin cancer. World J Surg Oncol, 12:159.
Lomas A, Leonardi-Bee J, Bath-Hextall F (2012). A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol, 166(5):1069-80.
Griffin LL, Ali FR, Lear JT (2016). Non-melanoma skin cancer. Clin Med (Lond), 16(1):62–5.
Almahroos M, Kurban AK (2004). Ultraviolet carcinogenesis in nonmelanoma skin cancer part II: Review and update on epidemiologic correlations. Skinmed, 3(3):132–9.
IARC. A review of human carcinogens: radiation, vol. 100D (2012). Lyon, France: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer, World Health Organization.
Mitropoulos P, Norman R (2005). Occupational nonsolar risk factors of squamous cell carcinoma of the skin: a population-based case-controlled study. Dermatol Online J, 11(2):5.
Siemiatycki J, Richardson L, Straif K, et al (2004). Listing occupational carcinogens. Environ Health Perspect, 112(15): 1447–1459.
Yoshinaga S, Mabuchi K, Sigurdson AJ et al (2004). Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies. Radiology, 233(2):313-21.
Diepgen TL, Drexler H (2012). Occupational Skin Cancer, In: Rustemeyer T, Elsner P, John SM, Maibach H (Hrsgg): Kanerva's Oc-cupational Dermatology. 2nd edition (Vol. I). Springer, Heidelberg, New York, Dordrecht, London, pp. 65–77.
Espina C, Straif K, Friis S et al (2015). European Code against Cancer 4th Edition: Environment, occupation and cancer. Cancer Epidemiol, 39 (Suppl 1):S84–92.
Gawkrodger DJ (2004). Occupational skin cancers. Occup Med (Lond), 54(7):458–63.
Hashim D, Boffetta P (2014). Occupational and environmental exposures and cancers in developing countries. Ann Glob Health, 80(5):393–411.
Surdu S, Fitzgerald EF, Bloom MS et al (2013). Occupational exposure to arsenic and risk of nonmelanoma skin cancer in a multinational European study. Int J Cancer, 133(9):2182–91.
Almquist LM, Karagas MR, Christensen BC et al (2011). The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis, 32(3):327–30.
Binstock M, Hafeez F, Metchnikoff C, Arron ST (2014). Single-nucleotide polymorphisms in pigment genes and nonmelanoma skin cancer predisposition: a systematic review. Br J Dermatol, 171(4):713–21.
Martinez MA, Francisco G, Cabral LS et al (2006). Molecular genetics of non-melanoma skin cancer. An Bras Dermatol, 81(5):405–19.
Nan H, Xu M, Kraft P et al (2011). Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. Hum Mol Genet, 20(18):3718–24.
Surdu S, Fitzgerald EF, Bloom MS et al (2014). Polymorphisms in DNA repair genes XRCC1 and XRCC3, occupational exposure to arsenic and sunlight, and the risk of non-melanoma skin cancer in a European case-control study. Environ Res, 134:382–9.
Jiang DK, Wang WZ, Ren WH et al (2011). TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol, 131(1):220–8.
Liu T, Lei Z, Pan Z et al (2014). Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma. Tumour Biol, 35(4):3899–903.
Yang X, Yang B, Liu Y et al (2013). The association between TP53 Arg72pro polymorphism and non-melanoma skin cancer risk: a meta-analysis including 7,107 subjects. Indian J Dermatol, 58(3):175–80.
Kim JW, Lee CG, Park YG et al (2000). Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer, 88(9):2082–91.
Wu X, Zhao H, Amos CI et al (2002). P53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst, 94(9):681–90.
Murata M, Tagawa M, Kimura H et al (1998). Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol, 12(3):577–81.
Storey A, Thomas M, Kalita A et al (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 393(6682):229–34.
Li C, Chen K, Liu Z et al (2008). Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneus melanoma. J Invest Dermatol, 128(6):1585–8.
Liang H, Lunec J (2005). Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene. Gene, 361:112–8.
Gemignani F, Moreno V, Landi S et al (2004). A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene, 23(10):1954–6.
Hu Z, Li X, Qu X et al (2010). Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis, 31(4):643–7.
Mavridou D, Gornall R, Campbell IG, Eccles, DM (1998). TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer, 77(4):676–7.
Wu D, Zhang Z, Chu H et al (2013). Intron 3 sixteen base pairs duplication polymorphism of p53 contributes to breast cancer susceptibility: evidence from meta-analysis. PLoS One, 8(4):e61662.
Ye XH, Bu ZB, Feng J et al (2014). Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep, 41(1):373–85.